UA80809C2 - Process for preparation of protective antigen protein of anthracis with e.coli - Google Patents
Process for preparation of protective antigen protein of anthracis with e.coli Download PDFInfo
- Publication number
- UA80809C2 UA80809C2 UA20040503327A UA20040503327A UA80809C2 UA 80809 C2 UA80809 C2 UA 80809C2 UA 20040503327 A UA20040503327 A UA 20040503327A UA 20040503327 A UA20040503327 A UA 20040503327A UA 80809 C2 UA80809 C2 UA 80809C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cells
- medium
- protective antigen
- protein
- recombinant
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 101710194807 Protective antigen Proteins 0.000 title claims abstract description 22
- 241000588724 Escherichia coli Species 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 230000008569 process Effects 0.000 title abstract description 4
- 241000193738 Bacillus anthracis Species 0.000 claims abstract description 8
- 108091007433 antigens Proteins 0.000 claims abstract description 3
- 102000036639 antigens Human genes 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 69
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 235000010469 Glycine max Nutrition 0.000 claims description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
- 238000004113 cell culture Methods 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 16
- 244000068988 Glycine max Species 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000004202 carbamide Substances 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 9
- 238000005119 centrifugation Methods 0.000 claims description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- 150000003077 polyols Chemical class 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 230000007928 solubilization Effects 0.000 claims description 2
- 238000005063 solubilization Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 229910052799 carbon Inorganic materials 0.000 description 18
- 235000011187 glycerol Nutrition 0.000 description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229960002235 anthrax antigen Drugs 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000013578 denaturing buffer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- -1 ammonium ions Chemical class 0.000 description 1
- 229960005447 anthrax vaccines Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000006860 carbon metabolism Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
- Laminated Bodies (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1127DE2001 IN190590B (de) | 2001-11-05 | 2001-11-05 | |
| PCT/IN2001/000215 WO2003040179A1 (en) | 2001-11-05 | 2001-12-07 | High level constitutive production of anthrax protective antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80809C2 true UA80809C2 (en) | 2007-11-12 |
Family
ID=11097131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040503327A UA80809C2 (en) | 2001-11-05 | 2001-07-12 | Process for preparation of protective antigen protein of anthracis with e.coli |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7329513B2 (de) |
| EP (1) | EP1442052B1 (de) |
| JP (1) | JP2005510215A (de) |
| CN (1) | CN100347189C (de) |
| AT (1) | ATE484517T1 (de) |
| BR (1) | BRPI0117173A2 (de) |
| CA (1) | CA2465679A1 (de) |
| DE (1) | DE60143276D1 (de) |
| HK (1) | HK1072610A1 (de) |
| IL (1) | IL161725A0 (de) |
| IN (1) | IN190590B (de) |
| MX (1) | MXPA04004281A (de) |
| RU (1) | RU2288272C2 (de) |
| UA (1) | UA80809C2 (de) |
| WO (1) | WO2003040179A1 (de) |
| ZA (1) | ZA200403396B (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA80809C2 (en) * | 2001-11-05 | 2007-11-12 | Process for preparation of protective antigen protein of anthracis with e.coli | |
| AU2004272972A1 (en) | 2003-05-22 | 2005-03-24 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
| WO2004108750A1 (en) * | 2003-06-06 | 2004-12-16 | Avecia Limited | Process for the separation of proteins |
| US20060246079A1 (en) * | 2003-11-14 | 2006-11-02 | Morrow Phillip R | Neutralizing human antibodies to anthrax toxin |
| WO2005081749A2 (en) * | 2004-01-23 | 2005-09-09 | Avanir Pharmaceuticals, Inc. | Neutralizing human antibodies to anthraxtoxin |
| US7355027B2 (en) | 2004-06-16 | 2008-04-08 | Dynport Vaccine Company Llc | Bacillus anthracis protective antigen |
| US8101735B2 (en) | 2004-06-16 | 2012-01-24 | Health Protection Agency | Preparation of protective antigen |
| CN100336908C (zh) * | 2004-09-10 | 2007-09-12 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种制备重组炭疽保护性抗原的方法及其专用表达质粒 |
| EP1919504B1 (de) | 2005-08-03 | 2013-10-16 | iBio, Inc. | Antikörper gegen bacillus anthracis protektiv antigen |
| EP1984405A4 (de) | 2006-02-13 | 2010-06-30 | Fraunhofer Usa Inc | Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren |
| WO2008048344A2 (en) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
| GB0607462D0 (en) * | 2006-04-13 | 2006-05-24 | Avecia Ltd | Assay |
| WO2007145760A2 (en) * | 2006-05-12 | 2007-12-21 | Oklahoma Medical Research Foundation | Anthrax compositions and methods of use and production |
| US8420607B2 (en) | 2006-06-30 | 2013-04-16 | University Of Georgia Research Foundation, Inc. | Anthrax carbohydrates, synthesis and uses thereof |
| AU2007349310B2 (en) | 2006-06-30 | 2013-03-14 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS OF DISEASE CONTROL AND PREVENTION (WASHINGTON D.C.) | Anthrax carbohydrates,synthesis and uses thereof |
| CA2692933C (en) | 2007-07-11 | 2016-10-18 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
| WO2009126355A2 (en) * | 2008-01-28 | 2009-10-15 | Baxter International, Inc. | Methods of increasing recombinant production of bacillus anthracis protective antigen |
| US8734803B2 (en) | 2008-09-28 | 2014-05-27 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
| CA2738621C (en) | 2008-10-02 | 2017-01-31 | Pharmathene Inc. | Anthrax vaccine formulation and uses thereof |
| US20100183675A1 (en) * | 2009-01-22 | 2010-07-22 | Allan Watkinson | Stable vaccine compositions and methods of use |
| US8784819B2 (en) | 2009-09-29 | 2014-07-22 | Ibio Inc. | Influenza hemagglutinin antibodies, compositions and related methods |
| US20120301951A1 (en) * | 2010-11-18 | 2012-11-29 | E. I. Du Pont De Nemours And Company | Prevention of contamination of nutrient feed reservoirs & feed lines in bioreactor systems |
| RU2633508C1 (ru) * | 2016-12-27 | 2017-10-12 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) | Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц |
| RU2633504C1 (ru) * | 2016-12-27 | 2017-10-12 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) | Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц |
| CN115125224B (zh) * | 2022-08-11 | 2023-07-18 | 福州大学 | 一种可规模化生产具有活性的dna聚合酶的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800821A (en) * | 1995-03-10 | 1998-09-01 | New England Medical Center Hospitals, Inc. | Bacterial spores as a heat stable vaccine delivery system |
| WO1999051733A2 (en) * | 1998-04-07 | 1999-10-14 | Wisconsin Alumni Research Foundation | Enterotoxin-deficient bacillus |
| US20020086032A1 (en) * | 1999-02-02 | 2002-07-04 | Mahan Michael J. | Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity |
| US7193126B2 (en) * | 2001-10-01 | 2007-03-20 | The Regents Of The University Of California | Method for generating overexpression of alleles in genes of unknown function |
| UA80809C2 (en) * | 2001-11-05 | 2007-11-12 | Process for preparation of protective antigen protein of anthracis with e.coli | |
| US7763451B2 (en) * | 2001-11-09 | 2010-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for preparing Bacillus anthracis protective antigen for use in vaccines |
-
2001
- 2001-07-12 UA UA20040503327A patent/UA80809C2/uk unknown
- 2001-11-05 IN IN1127DE2001 patent/IN190590B/en unknown
- 2001-12-07 CN CNB018239226A patent/CN100347189C/zh not_active Expired - Fee Related
- 2001-12-07 JP JP2003542224A patent/JP2005510215A/ja active Pending
- 2001-12-07 US US10/494,680 patent/US7329513B2/en not_active Expired - Fee Related
- 2001-12-07 DE DE60143276T patent/DE60143276D1/de not_active Expired - Lifetime
- 2001-12-07 MX MXPA04004281A patent/MXPA04004281A/es not_active Application Discontinuation
- 2001-12-07 AT AT01274653T patent/ATE484517T1/de not_active IP Right Cessation
- 2001-12-07 IL IL16172501A patent/IL161725A0/xx unknown
- 2001-12-07 BR BRPI0117173A patent/BRPI0117173A2/pt not_active IP Right Cessation
- 2001-12-07 CA CA002465679A patent/CA2465679A1/en not_active Abandoned
- 2001-12-07 RU RU2004117085/13A patent/RU2288272C2/ru not_active IP Right Cessation
- 2001-12-07 EP EP01274653A patent/EP1442052B1/de not_active Expired - Lifetime
- 2001-12-07 WO PCT/IN2001/000215 patent/WO2003040179A1/en active Application Filing
-
2004
- 2004-05-05 ZA ZA200403396A patent/ZA200403396B/en unknown
-
2005
- 2005-06-23 HK HK05105241A patent/HK1072610A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2288272C2 (ru) | 2006-11-27 |
| DE60143276D1 (de) | 2010-11-25 |
| JP2005510215A (ja) | 2005-04-21 |
| US20050054038A1 (en) | 2005-03-10 |
| IN190590B (de) | 2003-08-09 |
| EP1442052A1 (de) | 2004-08-04 |
| WO2003040179A1 (en) | 2003-05-15 |
| RU2004117085A (ru) | 2005-03-27 |
| ZA200403396B (en) | 2005-08-05 |
| ATE484517T1 (de) | 2010-10-15 |
| EP1442052B1 (de) | 2010-10-13 |
| BRPI0117173A2 (pt) | 2018-04-17 |
| MXPA04004281A (es) | 2005-03-31 |
| CA2465679A1 (en) | 2003-05-15 |
| CN100347189C (zh) | 2007-11-07 |
| CN1582298A (zh) | 2005-02-16 |
| IL161725A0 (en) | 2005-11-20 |
| HK1072610A1 (en) | 2005-09-02 |
| US7329513B2 (en) | 2008-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA80809C2 (en) | Process for preparation of protective antigen protein of anthracis with e.coli | |
| Park et al. | Enhanced β‐galactosidase production by high cell‐density culture of recombinant Bacillus subtilis with glucose concentration control | |
| Tsuchiya et al. | Effect of homogeneous and inhomogeneous high magnetic fields on the growth of Escherichia coli | |
| ES2728169T3 (es) | Procedimiento de cultivo de células de E. coli para alta densidad | |
| Brown et al. | Continuous production of human leukocyte interferon with Escherichia coli and continuous cell lysis in a two stage chemostat | |
| CN110317803A (zh) | 麦角硫因的纳米生物学制备方法 | |
| Szweda et al. | Efficient production of Staphylococcus simulans lysostaphin in a benchtop bioreactor by recombinant Escherichia coli | |
| Park et al. | Secretory production of recombinant protein by a high cell density culture of a protease negative mutant Escherichia coli strain | |
| Strandberg et al. | Large-scale fermentation and purification of a recombinant protein from Escherichia coli | |
| CN102321643B (zh) | 一条编码adi的优化dna分子及表达adi的工程菌 | |
| Joachim et al. | Process intensification for an insect antimicrobial peptide elastin-like polypeptide fusion produced in redox-engineered Escherichia coli | |
| Listner et al. | A simple method for the production of plasmid DNA in bioreactors | |
| CN104561200A (zh) | 一种有效改善重组蛋白在大肠杆菌中可溶性表达的方法 | |
| Kratje et al. | Evaluation of production of recombinant human interleukin‐2 in fluidized bed bioreactor | |
| CN105349561A (zh) | 一种利用血红蛋白提高发酵细胞密度的方法 | |
| CN102776260A (zh) | 一种高效表达重组人凝血八因子的方法 | |
| Huang et al. | Enhanced human lysozyme production by Kluyveromyces lactis | |
| CN108251375B (zh) | 一种发酵生产重组人白介素-12的方法 | |
| CN104694523A (zh) | 一种精氨酸脱亚胺酶的胞外表达方法及其应用 | |
| CN102533841B (zh) | 一种提高Bt杀虫蛋白在汉逊酵母中表达量的方法 | |
| CN106520821B (zh) | 适用于链霉菌的T7RNA聚合酶表达盒PhT7及其表达载体和应用 | |
| Feng et al. | Effect of temperature on synthesis of clavulanic acid and impurity substance G during fermentation by Streptomyces clavuligerus | |
| CN109593701A (zh) | 一种耐酸重组乳酸菌及其构建方法 | |
| EA025626B1 (ru) | ПРОДУЦЕНТ ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА ЧЕЛОВЕКА (рчЭФР) | |
| CN113999834B (zh) | 精氨酸脱亚胺酶生产菌及其构建方法 |